FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB	AP	PR	ovai
-----	----	----	------

OMB Number:	3235-0287
Estimated average burden	
hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

affirmative defense 10b5-1(c). See Insti						
Name and Address of Reporting Person* McManus Matthew			2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH]		tionship of Reporting Personall applicable) Director	on(s) to Issuer
(Last) 614 MCKINLEY	(First) PLACE NE	I	3. Date of Earliest Transaction (Month/Day/Year) 08/15/2025		Officer (give title below) President - Diag &	Other (specify below)
(Street) MINNEAPOLIS (City)	MN (State)	55413 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv	idual or Joint/Group Filing Form filed by One Repo Form filed by More than	` '. '

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr.		4. Securities Ad Disposed Of (D			Following Reported	Form: Direct (D)	Beneficial Ownership
			Code	v	Amount (A) or (D) Price		Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	08/15/2025		M		2,637	A	\$0	5,615	D	
Common Stock	08/15/2025		F		880	D	\$53.6	4,735	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Transaction(s) (Instr. 4)		
Performance Restricted Stock Units	(1)							(2)	(2)	Common Stock	2,888		2,888	D	
Performance Stock Option (Right to Buy)	\$68.54							(2)	02/01/2031	Common Stock	7,951		7,951	D	
Restricted Stock Units	(1)							(3)	(3)	Common Stock	9,241		9,241	D	
Stock Option (Right to Buy)	\$68.54							(4)	02/01/2031	Common Stock	15,902		15,902	D	
Performance Restricted Stock Units	(1)							(5)	(5)	Common Stock	15,825		15,825	D	
Restricted Stock Units	(1)	08/15/2025		М			2,637	(6)	(6)	Common Stock	2,637	\$0	5,275	D	
Stock Option (Right to Buy)	\$74.91							(7)	08/15/2034	Common Stock	21,320		21,320	D	
Performance Restricted Stock Units	(1)	08/15/2025		A		19,243		(8)	(8)	Common Stock	19,243	\$0	19,243	D	
Restricted Stock Units	(1)	08/15/2025		A		9,622		(9)	(9)	Common Stock	9,622	\$0	9,622	D	
Stock Option (Right to Buy)	\$53.6	08/15/2025		A		24,614		(10)	08/15/2035	Common Stock	24,614	\$0	24,614	D	

Explanation of Responses:

- 1. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- 2. Vests in full or in part on 8/15/2026 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- $3.\,4,\!620\ restricted\ stock\ units\ vest\ on\ 2/1/2025\ and\ 2/1/2027,\ and\ 4,\!621\ restricted\ stock\ units\ vest\ on\ 2/1/2026.$
- $4.\ Options\ to\ purchase\ 3,976\ shares\ vest\ on\ 2/1/2025\ and\ 2/1/2027, and\ options\ to\ purchase\ 3,975\ shares\ vest\ on\ 2/1/2026\ and\ 2/1/2028.$
- 5. Vests in full or in part on 8/15/2027 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- $6.\ 2,\!637\ restricted\ stock\ units\ vest\ on\ each\ of\ 8/15/2025\ and\ 8/15/2026, and\ 2,\!638\ restricted\ stock\ units\ vest\ on\ 8/15/2027.$

- 7. Options to purchase 5,330 shares vest on each of 8/15/2025, 8/15/2026, 8/15/2027 and 8/15/2028.
- 8. Vests in full or in part on 8/15/2028 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- 9. 3,207 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 3,208 restricted stock units vest on 8/15/2028.
- 10. Options to purchase 8,205 shares vest on each of 8/15/2026 and 8/15/2027, and options to purchase 8,204 shares vest on 8/15/2028.

/s/ Andrew Nick as Attorney-in-Fact for Matthew McManus pursuant to Power of Attorney previously filed.

08/19/2025

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.